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Abstract: The aim of this study was to determine the detailed anatomical structures of the superficial
part of the masseter and to elucidate the boundaries and locations of the deep tendon structure
within the superficial part of the masseter. Forty-four hemifaces from Korean and Thai embalmed
cadavers were used in this study. The deep tendon structure was located deep in the lower third of
the superficial part of the masseter. It was observed in all specimens and was designated as a deep
inferior tendon (DIT). The relationship between the masseter and DIT could be classified into three
types according to the coverage pattern: Type A, in which areas IV and V were covered by the DIT
(27%, 12/44); Type B, in which areas V and VI were covered by the DIT (23%, 10/44); and Type C,
in which areas IV, V, and VI were covered by the DIT (50%, 22/44). The superficial part of the masseter
consists of not only the muscle belly but also the deep tendon structure. Based on the results obtained
in this morphological study, we recommend performing layer-by-layer retrograde injections into the
superficial and deep muscle bellies of the masseter.
Keywords: superficial part of masseter muscle; paradoxical masseteric bulging; botulinum
neurotoxin Type A injection; lower facial contour
1. Introduction
The masseter is the most powerful jaw-closing muscle of the masticatory muscle group and is
more developed in Asians than in Caucasians. Some Asian women in particular are interested in
masseter reduction for improving the lower facial contour [1–4], and botulinum neurotoxin Type A
(BoNT-A) injection has been widely performed in recent years for treating masseteric hypertrophy [5–7].
BoNT-A injection treatment is known to be a noninvasive and safe alternative therapy to surgical
treatment for masseteric hypertrophy [8]. Since BoNT-A treatment was first reported by Moore (1994),
several side effects have been found in numerous anatomical and clinical studies, including swelling,
bruising, muscle weakness, and unexpected changes in the facial expression muscles [9,10].
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Various anatomical studies have attempted to determine the most effective BoNT-A injection
points and obtain optimal results while minimizing complications. Several of these studies have
investigated the intramuscular nerve distribution, the motor nerve entry point of the masseteric nerve
into the masseter, and the relationship between the parotid gland and the marginal mandibular branch
of the facial nerve [11–14]. However, the rare side effect of paradoxical masseteric bulging after
BoNT-A treatment for masseteric hypertrophy has not been investigated in any recent anatomical or
clinical studies.
Lee et al. (2012) reported the occurrence of paradoxical masseteric bulging after BoNT-A injection
into a hypertrophied masseter (Figure 1) [15]. Even though this is a rare sequela, clinical trials focused
on its anatomical clarification need to be performed. Therefore, the aim of this study was to determine
the detailed anatomical structures of the superficial part of the masseter and to elucidate the boundaries
and locations of the deep tendon structure within the superficial part of the masseter.
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2. Results
The deep tendon structure was located deep in the lower third of the superficial part of the
masseter. It was observed in all specimens and was designated as a deep inferior tendon (DIT).
The muscle fibers originating from the superficial aponeurosis of the masseter descended and then
changed into the DIT that attached to the inferior border of the mandible (Figure 2).













compartments  of  the masseter.  Type C  (66.7%,  14/21)  and  Type A  (39.1%,  9/23) were  the most 
common types in both the Korean and Thai cadaveric specimens. 
Figure 2. Detailed characteristics of the deep inferior tendon (DIT). (A) The DIT was located deep to
the superficial muscle belly of the superficial part of the masseter. (B) The muscle fibers originated
from the superficial aponeurosis of the masseter muscle, descended, and then changed into the tendon
structure attaching to the inferior mandibular border. White arrowheads indicate the muscle fibers that
originate from the deep to the superficial aponeurosis of the masseter muscle. A: anterior; S: superior;
OOr: orbicularis oculi muscle.
The relationship between the masseter and DIT could be classified into three types according to
the coverage pattern: Type A, in which areas IV and V were covered by the DIT (27%, 12/44); Type B,
in which areas V and VI were covered by the DIT (23%, 10/44); and Type C, in which areas IV, V,
and VI were covered by the DIT (50%, 22/44) (Figure 3). Thus, the DIT typically covered the lower
three compartments of the masseter. Type C (66.7%, 14/21) and Type A (39.1%, 9/23) were the most
common types in both the Korean and Thai cadaveric specimens.
The proportion of the DIT in the superficial part of the masseter was measured using an image
analysis program. The area of the superficial part of the masseter was 22.22 ± 4.2 cm2 (mean ± SD),
and that of the DIT was 4.48 ± 2.2 cm2, thereby constituting approximately 22% of the superficial part
of the masseter (19% in the Korean cadavers and 25% in the Thai cadavers) (Figure 4).
The DIT arose deep in the superficial aponeurosis of the masseter, ran downward, and then
changed into a tendon attaching to the inferior border of the mandible. Another muscle fiber that
originated from the zygomatic arch was present deep in the DIT. The middle and deep muscle fibers of
the masseter were observed to be deeper than this muscle fiber. In the deeper part, the periosteum was
found attached to the lateral aspect of the mandible (Figure 5).










Figure 3. Classification of the DIT. The DIT can be found easily after removing the superficial muscle
belly of the superficial part of the masseter. (A) Type A in which the DIT covers areas IV and V.
(B) Type B in which the DIT covers areas V and VI. (C) Type C in which the DIT covers areas IV, V,
and VI.
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Figure  4.  Proportions  of  the DIT  in  the  superficial  part  of  the masseter. The  surface  area  of  the 
superficial part of the masseter muscle was 22.22 ± 4.2 cm2 (A), and the DIT area within the masseter 
muscle was 4.48 ± 2.2 cm2 (B), hence constituting 22% of the superficial part of the masseter.   
Figure 4. Proportions of the DIT in the s erficial art f the asseter. The surface area of the
superficial part of the masseter muscle was 22.22 4.2 c 2 (A), and the DIT area within the masseter
muscle was 4.48 ± 2.2 c 2 (B), hence constituting 22% of the superficial part of the masseter.





(A) Surfaces of  the  superficial part of  the masseter.  (B) The DIT was exposed after  removing  the 














to  comprise  a  muscle  belly  only;  however,  we  found  that  the  superficial  layer  has  quite  a 
complicated structure composing of a deep and broad tendon within the muscle belly in the present 
study.  The  organization  of  the  entire  masseter  was  reported  in  2000,  and  those  results  were 
generally comparable to those obtained in the present study [16]. 
The DIT was  located  and  formed  deep  to  the  superficial  part  of  the masseter  and  broadly 
attached to the lower third of the mandibular ramus and the inferior border of the mandible (Figure 
4). Moreover, an additional thin muscle belly was observed deep to the DIT, and the insertion of the 
Fig re 5. Serial issectio s of t e layere str ct res of t e asseter scle fro s erficial to ee .
( ) rf ces f t e s erfici l rt f t e sseter. ( ) e I s e se fter re i t e
s rfici l muscle belly and the aponeurosis of the superficial part of the masseter. (C) Another muscle
belly was revealed aft r r moving the DIT. (D) The middle and deep p rts of the masseter muscle were
attach d at the l teral surface of the mandible and the periosteum.
3. Discussion
This is the first anato ical study to propose a echanis underlying paradoxical asseteric
bulging after BoNT-A injection. Based on the observations made in this study, it was hypothesized that
a broad tendon structure (i.e., the DIT) located within the superficial layer of the masseter may prevent
the spreading of BoNT-A into the entire layer of the superficial muscle belly (Figure 6A). This would
result in the deeper muscle belly of the superficial masseter usually being paralyzed, and in rare cases
bulging of a part of the superficial muscle belly that is unaffected by BoNT-A due to the presence of
the DIT (Figure 6B). The DIT originated deep to the aponeurosis of the superficial part of the masseter
in every case.
The asseter has been previously described as consisting of three layers: superficial, iddle,
and deep (zygomaticomandibularis muscle) [12]. The superficial layer has usually been considered to
comprise a muscle belly only; however, we found that the superficial layer has quite a complicated
structure composing of a deep and broad tendon within the muscle belly in the present study.
The organization of the entire masseter was reported in 2000, and those results were generally
comparable to those obtained in the present study [16].













the  superficial  belly  of  the  superficial  part  of  the  masseter  because  the  DIT  blocks  the  toxin’s 
diffusion. (SB: superficial muscle belly of superficial part of the masseter; DB: deep muscle belly of 
superficial  part  of  the masseter; DP: deep part  of  the masseter; DIT: deep  inferior  tendon;  SaM: 
superficial aponeurosis of the masseter). 
The  most  common  injection‐based  method  for  treating  masseteric  hypertrophy  involves 
injecting  BoNT‐A  either  deep  into  the  lower  third  of  the masseter  or where  it  bulges  the most 
[5,17,18]. This method  is designed  to  avoid damage  to  the  facial nerve  and  the  superficial  facial 
muscles  such  as  the  risorius  and  zygomaticus minor muscles, which  could  result  in unexpected 
changes in facial expression and paralysis of the buccinator and pterygoid muscles [2,19–21]. 
The DIT was located in the lower third of the masseter in every case, but its morphology varied 
slightly between  the Korean and Thai specimens. The most common  type  in the Korean cadavers 
was Type C, which covered areas IV, V, and VI (66.7% of specimens), while Type A, which covered 
areas  IV  and  V  (39.1%  of  specimens),  was  the  most  common  in  the  Thai  cadavers.  These 
observations  imply  that  the  injection  techniques applied  to Korean  and Thai patients need  to be 
modified in order to optimize the treatment of masseteric hypertrophy. Even though Type C (areas 
IV, V, and VI)  is  the most common  type  in Koreans, area VI  is known  to be a vulnerable  region 
since it is covered by the risorius muscle. 
Figure 6. The illustration of the coronal section of the masseter from superficial to deep (A) and the
expected muscle feature showing the masseteric bulging after the BTX-A injection into the masseter
muscle during clenching (B). When masseter contracts, paradoxical masseteric bulging may occur at
the superficial belly of the superficial part of the masseter because the DIT blocks the toxin’s diffusion.
(SB: superficial muscle belly of superficial part of the masseter; DB: deep muscle belly of superficial part
of the masseter; DP: deep part of the masseter; DIT: deep inferior tendon; SaM: superficial aponeurosis
of the masseter).
The DIT was located and formed deep to the superficial part of the masseter and broadly attached
to the lower third of the mandibular ramus and the inferior border of the mandible (Figure 4). Moreover,
an additional thin muscle belly was observed deep to the DIT, and the insertion of the deep part of
the masseter and periosteum was observed underneath this deeper thin muscle layer. Based on our
findings, the superficial part of the masseter appears as lamellar structures consisting of the overlapped
muscle belly and deep tendon structure. Thus, the superficial layer to the deep layer of the masseter
were organized in the following order: superficial muscle belly of the masseter, DIT, deeper muscle
belly, and insertion of the middle and deep parts of the masseter and periosteum (Figure 6).
The most common injection-based method for treating masseteric hypertrophy involves injecting
BoNT-A either deep into the lower third of the masseter or where it bulges the most [5,17,18].
This method is designed to avoid damage to the facial nerve and the superficial facial muscles
such as the risorius and zygomaticus minor muscles, which could result in unexpected changes in
facial expression and paralysis of the buccinator and pterygoid muscles [2,19–21].
The DIT was located in the lower third of the masseter in every case, but its morphology varied
slightly between the Korean and Thai specimens. The most common type in the Korean cadavers
was Type C, which covered areas IV, V, and VI (66.7% of specimens), while Type A, which covered
areas IV and V (39.1% of specimens), was the most common in the Thai cadavers. These observations
imply that the injection techniques applied to Korean and Thai patients need to be modified in order
to optimize the treatment of masseteric hypertrophy. Even though Type C (areas IV, V, and VI) is the
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most common type in Koreans, area VI is known to be a vulnerable region since it is covered by the
risorius muscle.
Paradoxical masseteric bulging occurs in rare cases after BoNT-A injections into the masseter [15]
and has been discussed only anecdotally in the clinical field, with no detailed anatomical information
available about the fundamental underlying cause. The current results show clearly that the DIT can
prevent the toxin from spreading into the entire superficial masseter during the BoNT-A injection
procedure. That is, the DIT acts as a window within the superficial masseter that can confine the
injected toxin to within the deeper muscle belly.
Ultimately, the superficial part of the masseter consists of not only the muscle belly but also the
deep tendon structure. Considering that the deep tendon structure was present in every specimen of
the present study, physicians should be aware of this tendon prior to treating masseteric hypertrophy
and improving lower face contouring using BoNT-A injections. Knowledge of this critical anatomical
information will help to prevent paradoxical masseteric bulging. Based on the results obtained in
this morphological study, we recommend performing layer-by-layer retrograde injections into the
superficial and deep muscle bellies of the masseter (Figure 6).
4. Materials and Methods
Signed and informed consent was obtained from the volunteer. Forty-four hemifaces from Korean
(21 hemifaces, 10 left and 11 right; mean age 79.9 years) and Thai (23 hemifaces, 11 left and 12 right;
mean age 68.6 years) embalmed cadavers were dissected to analyze the morphological patterns,
with 30 of them used to measure the detailed location of the deep tendon structure of the masseter.
The skin of the midface was carefully removed, and the superficial musculoaponeurotic
system (SMAS), parotid gland, and masseteric fascia were dissected to reveal the entire masseter.
The superficial part of the masseter was dissected to expose and observe the morphological patterns
and location of the deep tendon structure.
The surface of the superficial part of the masseter was classified into six equivalently sized
rectangular areas (designated I to VI) to enable the portion covered by the deep tendon structure to
be delineated. Areas I–III and IV–VI were designated as the upper and lower three compartments,
respectively. The location of the deep tendon structure was categorized according to its position with
respect to these six compartments.
The proportion of the deep tendon structure in the superficial part of the masseter was measured
using an image analysis program (I-solution, IMTechnology, Coquitlam, BC, Canada).
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